GlassScriptPhysician profile
Jonathan M Gerard
NPI 1780099697
$3,390.77
in general payments reported to CMS, 2019-2025
21 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.56 · 2020: $43.34 · 2022: $485 · 2023: $855 · 2024: $951 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,820.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $668.15 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $498.47 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $485.39 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $394.86 | 2022-2025 | Xiidra, Vyzulta, Lotemax Sm |
| Alcon Vision LLC | $308.41 | 2022-2025 | Rocklatan, Eysuvis, Rhopressa |
| Biotissue Holdings INC. | $246.38 | 2022-2025 | |
| Dompe US, INC. | $156.47 | 2024-2025 | Oxervate |
| Abbvie INC. | $109.86 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $97.76 | 2019-2023 | |
| Harrow Eye, LLC | $85.60 | 2024-2025 | Vevye |
| Thea Pharma INC. | $60.09 | 2023-2025 | Iyuzeh |
| Sight Sciences, INC. | $51.38 | 2025 | Tearcare System |
| Regeneron Healthcare Solutions, INC. | $50.69 | 2022-2023 | Eylea |
| Johnson & Johnson Surgical Vision, INC. | $42.07 | 2023 | Tecnis Iol, Catalys System, Tecnis Simplicity |
| Apellis Pharmaceuticals, INC. | $36.05 | 2025 | Syfovre |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $18.59 | 2024 | Myday Contact Lens |
| Amgen INC. | $17.53 | 2024 | Tepezza |
| Ani Pharmaceuticals, INC. | $17.47 | 2025 | Purified Cortrophin Gel |
| Johnson & Johnson Vision Care, INC. | $15.96 | 2023 | Acuvue |
| Eyevance Pharmaceuticals LLC | $14.97 | 2022 | |
| Kala Pharmaceuticals, INC. | $14.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Gerard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.